碱基编辑的造血干/祖细胞X连接严重的免疫缺陷基因治疗
1/2阶段基本编辑的造血茎/祖细胞X连锁严重的免疫缺陷基因治疗
Background:
X-linked severe combined immunodeficiency (XSCID) is a rare inherited disorder that affects the immune system. It is caused by a change in the IL2RG gene. Researchers are investigating a new type of gene therapy for people with XSCID. This technique, called base-edited stem cell transplants, involves collecting a person s own stem cells, editing the genes to repair IL2RG gene, and returning the edited cells to the person.
Objective:
To test base-edited stem cell transplants in people with XSCID.
Eligibility:
People aged 3 years and older with XSCID.
Design:
Participants will be screened. They will have a physical exam. They may give blood, urine, and stool samples. They may have tests of their heart and lung function. They may have fluid and cells drawn from their bone marrow.
Participants will undergo apheresis. Blood will be taken from the body through a needle inserted into 1 arm. The blood will pass through a machine that separates out the stem cells. The remaining blood will be returned to the body through a different needle. The collected stem cells will undergo gene editing.
Participants will be admitted to the hospital 1 week before treatment. They will receive a central line: A flexible tube will be inserted into a large vein. This tube will be used to administer drugs and draw blood during their stay. They will receive drugs to prepare their bodies for the treatment.
The base-edited stem cells will be infused through the central line. Participants will remain in the hospital for at least 3 weeks while they recover.
Follow-up visits will continue for 15 years.
...
研究概览
地位
详细说明
Study Description:
This is a phase 1/2, non-randomized study of a single infusion of autologous hematopoietic stem/progenitor cells base-edited to repair interleukin 2 receptor gamma (IL2RG) mutations (BE-HSPC IL2RG) in 18 participants with X-linked severe combined immunodeficiency (X-SCID).
Primary Objective:
Evaluate the safety of treatment with BE-HSPC IL2RG in participants with X-SCID.
Secondary Objectives:
Evaluate efficacy of treatment with BE-HSPC IL2RG in participants with X-SCID.
Exploratory Objectives:
- Evaluate off-target (OT) editing activity.
- Compare outcomes of immune reconstitution with lentivector (LV) gene therapy.
Primary Endpoint:
Safety of treatment with BE-HSPC IL2RG, by quantifying frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Secondary Endpoints (24 months post-study agent infusion):
-
Percentage of participants with >=5% mutation-repaired myeloid cells.
-
Editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).
-
Immune reconstitution:
- T, B, and NK cell number improvement from baseline.
- Emergence of naive T cells and CD31+ recent thymic emigrants.
- B-cell function: immunoglobulin (Ig) production.
- Specific responses to vaccines.
-
Clinical efficacy: improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.
-
Frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.
Exploratory Endpoints:
- Evaluate for frequency of off-targets (OTs) by high-throughput sequencing (HTS) of the target mutation at 2 years post-infusion.
- Compare rates of immune reconstitution with LV-X-SCID gene therapy.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- National Institutes of Health Clinical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Aged >= 3 years and weigh >=10 kg
- Patients with X-SCID
- If previously transplanted, must be >=18 months post-HSCT
- Expected survival of at least 120 days.
- Ability to undergo apheresis for stem cell collection.
- Patients with proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA. At this time, only patients with an IL2RG p.Q144X, IL2RG p.R289X, IL2RG p.Q235X and IL2RG p.R226H mutations can be treated.
- Participants of reproductive potential must agree to consistently use highly effective contraception throughout study participation and for at least 2 years post-treatment.
Acceptable forms of contraception are:
--For males: Condoms or other contraception with partner.
- Documented to be negative for HIV infection by PCR
- The patient must be judged by the primary evaluating physician to have a suitable family and social situation consistent with ability to comply with protocol procedures and the long-term follow-up requirements.
- Medical lab data (historical) of severe B cell dysfunction (low or absent IgG levels, failed immune response to vaccines);
OR
demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels).
-Must be willing to have blood and tissue samples stored IN ADDITION, patients must satisfy the following Laboratory Criteria AND Clinical Criteria
Laboratory Criteria: (>=1 must be present)
- CD4+ lymphocytes: absolute number <= 50% of the lower limit of normal (LLN)
- CD4+CD45RA+ lymphocytes: absolute number <= 50% of the LLN OR T-cell receptor excision circles (TRECs) <= 5% of normal for age.
- Memory B Cells: absolute number <= 50% of LLN
- Serum IgM<normal for age
- NK cells: absolute number <= 50% of LLN
- Lymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is <= 25% compared with a normal control.
- Molecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in >=6 of the 24 V(Beta) T-cell receptor families.
Clinical Criteria: (>=1 must be present)
I. Infections (not including molluscum, warts or mucocutaneous candidiasis; see VII and VIII below):
Three significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criterion.
Infections are defined as an objective sign of infection
- (fever >=38.3 degrees Celsius (101 degrees Fahrenheit) or
- neutrophilia or
- pain/redness/swelling or
- radiologic/ultrasound imaging evidence or
- typical lesion or histology or
- new severe diarrhea or
- cough with sputum production.
In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician s intent to treat a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)
-
Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics >=14 days
OR
-
Hospitalization of any duration for infection
OR
-
Isolation of a bacteria, fungus, or virus from biopsy, skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection
II. Chronic pulmonary disease as defined by:
-
Bronchiectasis by x-ray computerized tomography
OR
-
Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60% of Predicted for Age
OR
-
Pulse oximetry <=94% in room air (if patient is too young to comply with performance of PFTs).
III. Gastrointestinal enteropathy:
-
Diarrhea-watery stools >=3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion I. above)
OR
-
Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated)
OR
-
Other evidence of enteropathy or bacterial overgrowth syndrome: including malabsorption of fat soluble vitamin(s), abnormal D-xylose absorption, abnormal hydrogen breath test, evidence of protein losing enteropathy (for example increasingly high or frequent dosing of intravenous gamma globulin supplement required to maintain blood IgG level).
IV. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.
V. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes at more than one anatomic site and not due to infection, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.
VI. Failure to grow in height: <=3rd percentile for age
VII. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of >=10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are >=3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts)
VIII. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)
IX. Hypogammaglobulinemia: requires regular IgG supplementation
Criteria for eligibility for Campath:
Evidence of organ disease attributable to T cell dysregulation (e.g., elevated transaminases)
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Available HLA-matched sibling donors.
- Known hypersensitivity to busulfan or any component of the product.
- Contraindications for administration of busulfan.
- Childhood malignancy (occurring before 18 years of age) in the participant or a first degree relative, or previously diagnosed known genotype of the participant conferring a predisposition to cancer unless approved by the Hematology consult team (no DNA or other testing for cancer predisposition genes will be performed as part of the screen for this protocol).
- Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the participant, or would preclude the patient from successful study completion.
- Unwilling to submit their information as part of the alemtuzumab (Campath(R)) Distribution Program application or the Distribution Program committee has determined the participant is not qualified to receive alemtuzumab.
NOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:单臂研究
|
Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection. Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection. Mucositis prophylaxis: As is standard practice prior to busulfan conditioning, IV infusion of keratinocyte growth factor (palifermin) will be administered at 60 micrograms/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3). Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). For this study, busulfan is administered once daily (3 mg/kg) x 2 days, targeting a daily busulfan AUC of 4500-6500 micromol*min/L or a cumulative AUC of 9000 micromol*min/L (for the 2 days of therapy if levels are available. Busulfan will be infused over 3 hours each day as per standard clinical practice. Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. A one-time dose >5(SqrRoot) 10^6 base-edited cells/kg body weight will be administered to each participant. The exact dosage depends on the number of viable cells that are repaired, cryopreserved, and thawed. The study agent will be administered by IV infusion in a volume of approximately 50 mL over about 15-30 minutes, in accordance with NIH CC DTM infusion policy. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
大体时间:12 months
|
Evaluate the safety of treatment with BE-HSPC IL2RG in participants with X-SCID. |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate percentage of participants with >= 5% mutation-repaired alleles in PBMCs.
大体时间:24 months
|
Measure efficacy of treatment by assessing efficiency of base editor at repair of mutations. |
24 months
|
|
Evaluate editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).
大体时间:24 months
|
Measure efficacy of treatment by assessing molecular evidence for mutation repair. |
24 months
|
|
Evaluate Immune reconstitution: a. T, B, and NK cell number improvement from baseline. b. Emergence of naive T cells and CD31+ recent thymic emigrants.c. B-cell function: immunoglobulin (Ig) production. d. Specific responses to vacci...
大体时间:24 months
|
Measure efficacy of treatment by assessing immune reconstitution as indicated by 1) increase in immune cell numbers; 2) restoration of thymic function with production of na(SqrRoot) ve T cells and CD31+ T cells; 3) Evaluate restoration of B-cell function. |
24 months
|
|
Evaluate clinical efficacy by improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.
大体时间:24 months
|
Measure efficacy of treatment by assessing comparison of clinical status before and after treatment as indicator of response to improved immune function. |
24 months
|
|
Evaluate frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.
大体时间:24 months
|
Measure efficacy of treatment by assessing intervention-related AE rate. |
24 months
|
合作者和调查者
调查人员
- 首席研究员:Suk S De Ravin, M.D.、National Institute of Allergy and Infectious Diseases (NIAID)
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 10002273
- 002273-I
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.